Recent Updates
Recently added Catalysts
ACET Positive Sentiment

Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

Friday, September 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Adicet Bio, a clinical-stage biotechnology company, has announced a webcast to present clinical data from its Phase 1 study of prula-cel. This therapy is being evaluated for patients with systemic lupus erythematosus, with or without lupus nephritis. The presentation aims to share insights into the potential of prula-cel as a treatment option.

Market Sentiment Analysis

POSITIVE FACTORS

  • Adicet Bio is advancing its clinical research with prula-cel.
  • The Phase 1 study shows promise for treating systemic lupus erythematosus.
  • The webcast will provide valuable insights into clinical data.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+83%
120-day peak, hindsight
Typical move
1.6%
average across 3 past catalysts
Cash runway
~17 mo
Low dilution risk
Lead asset
ADI-212
Phase 1 · Prostate Cancer Metastatic

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis

Frequently Asked Questions

What is prula-cel?

Prula-cel, formerly known as ADI-001, is an allogeneic CAR-T therapy.

What disease is prula-cel targeting?

Prula-cel is being evaluated for systemic lupus erythematosus.

When will the webcast take place?

The specific date of the webcast has not been mentioned.

What phase is the prula-cel study in?

The study is currently in Phase 1.

ShareAdd on Google
Tags: ACET Viatris Investor Conferences Healthcare Adicet Bio prula-cel systemic lupus erythematosus lupus nephritis clinical trial
Last updated: Sep 25, 2026

Biotech snapshot

Cash runway
$118M liquidity · $7M/mo burn
~17 mo
Low dilution risk
Lead asset
ADI-212Phase 1
Prostate Cancer Metastatic →

Catalyst track record

+83%
best trade around ACET's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ACET.

See every catalyst's timing & PoA →